Yingpai Pharmaceuticals Wee1 inhibitors are declared clinical in China

According to the latest announcement from the Drug Review Center (CDE) of the State Drug Administration of China, Yingpai Pharmaceuticals submitted an application for a clinical trial in the study of Wee1 inhibitor IMP7068, which was accepted on December 7.
note that the drug had just been approved for clinical trials in the United States.
screenshot source: CDE website Wee1 is an important kinase associated with the DNA Damage Repair (DDR) path path, involved in the regulation of cell cycles, and plays a key role in G2/M checkpoints.
that Wee1 is one of the proven targets of cancer drug research, and there is a synthetic lethal effect with the widespread TP53 gene mutation in tumor cells.
, there are other Wee1 inhibitors in multiple tumors, especially tumors with TP53 mutations, demonstrating the clinical efficacy of proof-of-concept.
pharmaceutical industry focuses on the development of synthetic lethal mechanism of targeted anti-cancer drugs.
IMP7068 is a brand new compound developed by the company based on its own research and development platform for DNA damage repair paths, with British Pharmaceuticals having global intellectual property rights.
preclinical studies showed that IMP7068 showed good safety, toerability and pharmacodynamic characteristics in animals, and showed high anti-tumor activity in multiple tumor cell strains and animal models.
Based on the public information of Yingpai Pharmaceuticals, implying that IMP7068 is more selective based on the new molecular structure design, and that half-life and drug exposure in animals are better than those of similar drugs under study, and are expected to achieve better clinical safety.
November 2020, Indo-Pharmaceuticals announced that IMP7068 had received implied FDA clinical trial approval to launch its first clinical trial.
This is an open, multi-center, dose climbing and dose expansion phase 1 clinical study designed to evaluate the safety, toerability, pharmacodynamic characteristics and initial efficacy of the Wee1 inhibitor IMP7068 single drug in patients with advanced solid tumors.
that this clinical declaration in China means that IMP7068 is expected to start clinical trials in China soon.
References: China's State Drug Administration Drug Review Center. Retrieved Dec 8,2020, from The British Pharmaceuticals Wee1 inhibitor IMP7068 has been approved for entry into U.S. clinical trials. Retrieved Nov 13, 2020, From Source: Medical Mission Hills